Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.


Development of a sensitive and reliable ELISA kit of urinary haptoglobin to predict progress of diabetic kidney disease

January 27th 2021

We have generated an ELISA kit to accurately detect UHp levels, which is potentially a reliable biomarker of DKD (Diabetes/Metabolism Research and Reviews)

Categories: Nephropathy, News
Tags: ELISA

Categories: Nephropathy
Tags: ELISA

Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts

January 27th 2021

The UKPDS‐OM2 consistently overpredicted the risk of mortality and MI in both cohorts during follow‐up. Period effects may partially explain the differences. Results indicate that transferability is not satisfactory for all outcomes, and new or adjusted risk equations may be needed before applying the model to the Italian or Dutch settings (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Monitoring, News
Tags: Type 2 Diabetes

Categories: Cardiovascular, Monitoring
Tags: Type 2 Diabetes

Temporal Trends in Comorbidities and Cardiometabolic Risk Factors at the Time of Diagnosis of Type 2 Diabetes in UK

January 27th 2021

CMM and high ASCVD risk have been consistently increasing across all age groups and gender, particularly CMM in those <50 years. Our findings indicate that the ESC‐EASD recommendations need to change to consider the young‐onset people with T2DM as a high‐risk group as recommended in the Primary Care Diabetes Europe Position Statement (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, News
Tags: morbidity, Type 2 Diabetes

Categories: Cardiovascular
Tags: morbidity, Type 2 Diabetes

Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial

January 27th 2021

Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes. Clinicians and policy makers should ensure that metabolic surgery is appropriately considered in the management of patients with obesity and type 2 diabetes (The Lancet)

Categories: Bariatric, News
Tags: Type 2 Diabetes

Categories: Bariatric
Tags: Type 2 Diabetes

Lack of awareness of liver organ damage in patients with type 2 diabetes

January 26th 2021

Despite increasing evidence of a frequent hepatic involvement associated with poor prognosis, awareness of suffering of advanced liver disease in patients with T2D is remarkably low, likely reflecting little recognition also among the team of health care professionals (Acta Diabetologica)

Categories: News, Pathology
Tags: liver, Type 2 Diabetes

Categories: Pathology
Tags: liver, Type 2 Diabetes

Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis

January 26th 2021

The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

What’s in a Name? Redefining Type 2 Diabetes Remission

January 25th 2021

This opinion piece explores existing definitions of diabetes remission and proposes a contemporary and comprehensive framework to help define this clinical state

Categories: Management, News
Tags: remission, Type 2 Diabetes

Categories: Management
Tags: remission, Type 2 Diabetes

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes

January 21st 2021

As strategy-driven, head-to-head RCTs comparing SGLT-2i, GLP-1RA, or DPP-4i with metformin (and their combination with metformin) while ensuring glycemic and weight equipoise are unlikely to become available in the future, sharing and analyzing individual-level data from already conducted RCT would help to inform the evidence for the best first-line treatment(s) in subjects with type 2 diabetes and confirm or refute our finding (Diabetes Care)

Categories: News, Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Categories: Research
Tags: DPP-4i, GLP-1RA, metformin, SGLT2 inhibitors

Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study

January 21st 2021

Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression (Diabetes Care)

Categories: News, Treatment
Tags: Type 2 Diabetes

Categories: Treatment
Tags: Type 2 Diabetes

Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes

January 19th 2021

These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)

Categories: Medication, News
Tags: COVID-19, metformin

Categories: Medication
Tags: COVID-19, metformin

ABCD and ABHI Position on Insulin Pumps

January 19th 2021

ABCD and ABHI have released a joint position statement “Supporting Management of People with diabetes using Out-of-Warranty Pumps while Ensuring Appropriate Patient Choice”

Categories: News, Treatment
Tags: insulin pumps

Categories: Treatment
Tags: insulin pumps

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

January 19th 2021

Hyperglycaemia was reduced without increasing hypoglycaemia in adolescents and young adults with type 1 diabetes using the investigational advanced hybrid closed-loop system compared with the commercially available MiniMed 670G system (The Lancet)

Categories: News, Treatment
Tags: insulin pumps, pumps, Type 1 Diabetes

Categories: Treatment
Tags: insulin pumps, pumps, Type 1 Diabetes

National Diabetes Audit, Diabetes Prevention Programme (DPP), Quarterly Data Release, 1st January – 30th September 2020

January 14th 2021

The NHS Diabetes Prevention Programme (DPP) is a joint commitment from NHS England, Public Health England (PHE) and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia

Categories: Audits, News
Tags: NHS

Categories: Audits
Tags: NHS

Global Trials Summit

January 14th 2021

Please join us for a series of vibrant and thought-provoking presentations by leaders in these fields who will discuss the results of recent pivotal trials in these areas. Live online discussions focusing on implementation of novel efficacious therapies will challenge clinicians as to how to adapt their daily practice.

Categories: Education, News
Tags: trials

Categories: Education
Tags: trials

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

January 14th 2021

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)

Categories: Cardiovascular, Medication, News
Tags: sotagliflozin

Categories: Cardiovascular, Medication
Tags: sotagliflozin

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

January 13th 2021

In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with notable differences in benefits and harms (BMJ)

Categories: Medication
Tags: DPP4i, SGLT2 inhibitors

SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice

January 12th 2021

SGLT2is administration slows the decline observed in the annual renal function in T2DM patients with eGFR of < 60 ml/min/1.73m2, in clinical practice (Journal of Diabetes Investigation)

Categories: Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes

Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

January 12th 2021

This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i (Cardiovascular Diabetology)

Categories: Cardiovascular, Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

January 11th 2021

In propensity score-matched cohorts, GLP-1 RAs demonstrated significant benefits for both glycemic control and weight management over additional OAD(s) or insulin, respectively, indicating that they may represent the optimal choice at these points in the treatment pathway (BMJ Open, Diabetes Research & Care)

Categories: Medication, News
Tags: GLP1, Type 2 Diabetes

Categories: Medication
Tags: GLP1, Type 2 Diabetes

Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses

January 11th 2021

Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality (Diabetologia)

Categories: News, Pathology
Tags: Type 2 Diabetes

Categories: Pathology
Tags: Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 210
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskNapp DiabetesAstraZenecaSanofi Diabetes

Silver Sponsors

AmgenAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

News Archive

calendar-iconNews Archive ››

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Recent Book and Product Reviews

  • Oxford Handbook of Emergency Medicine
  • Handbook of Obstetric Medicine
  • Ferri’s Clinical Advisor 2021
  • Oxford Case Histories in Infectious Diseases and Microbiology

Recent Diabetes Updates

  • National Diabetes Audit.
  • Funding bids
  • Publication of Studies During 2016 – Type 2 Diabetes
  • “Attitudes to obesity” findings from the 2015 survey

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


Website by Wired up Wales

Copyright © 2021 Glycosmedia Partnership